In-hospital and Readmission Outcomes With Percutaneous Balloon Mitral Valvuloplasty |
| |
| Institution: | 1. Division of Cardiovascular Disease, Loyola University Medical Center, Loyola Stritch School of Medicine, Maywood, IL;2. Brown University, Providence, RI;3. Heart, Vascular and Thoracic Institute, Cleveland Clinic Foundation, Cleveland, OH;4. Mayo Clinic College of Medicine and Science, Department of Cardiovascular Medicine, Rochester, MN;5. Lifespan Cardiovascular Institute, Providence, RI;6. Division of Cardiology, Warren Alpert Medical School of Brown University, Providence, RI;1. Department of Medicine, Cleveland Clinic Akron General, Akron, Ohio, United States;2. Department of Cardiovascular Medicine, Maimonides Medical Center, NY, New York;3. Division of Cardiovascular Medicine, Krannert Cardiovascular Research Center, Indiana University School of Medicine, Indianapolis, IN;4. Department of Cardiovascular Medicine, Heart, Vascular, and Thoracic Institute, Cleveland Clinic, Cleveland, OH;5. Department of Cardiovascular Medicine, Lahey Hospital & Medical Center, Burlington, MA;6. Division of Cardiology, Department of Medicine, Cardiovascular Institute, Kalra Hospitals, New Delhi, India;1. Internal Medicine, University of Texas Medical Branch, Galveston, TX;2. Cardiology, University of Texas Medical Branch, Galveston, TX;1. Department of Medicine, University Hospitals, Cleveland, OH;2. Harrington Heart and Vascular Institute, University Hospitals and School of Medicine, Case Western Reserve University, Cleveland, OH;3. Department of Rheumatology, Bronson Rheumatology Specialists, Kalamazoo, MI;4. Louis Stokes Verteran Affairs Hospitals, Cleveland, OH;5. Loyola University Medical Center, Department of Cardiology, Maywood, IL;6. Minneapolis Heart Institute, Minneapolis, MN;7. Oklahoma University Stephenson Cancer Center, Oklahoma City, OK;8. University of Oklahoma Health Sciences, Oklahoma City, OK;1. General Surgery Resident, UT Health San Antonio, Texas, USA;2. Cleveland Clinic Abu Dhabi, UAE;3. Consultant Cardiothoracic Surgery, Cleveland Clinic Abu Dhabi, UAE;4. Consultant Cardiologist, Cleveland Clinic Ohio, USA;5. Rush University, Chicago, USA;1. Cardiorespiratory Emergencies, Hospital General de México “Dr Eduardo Liceaga”, 06720, Mexico City, Mexico;2. Pulmonary Circulation Clinic, Hospital General de México “Dr. Eduardo Liceaga”, 06720, Mexico City, Mexico;3. Faculty of Medicine, National Autonomous University of Mexico, Mexico City, Mexico;4. Pulmonology Department, Hospital General de México “Dr. Eduardo Liceaga”, 06720, Mexico City, Mexico;5. Directorate of Research, Hospital General de Mexico “Dr. Eduardo Liceaga,” 06720, Mexico City, Mexico;6. I.M. Sechenov First Moscow State Medical University (Sechenov University), Department of Radiology, 119992, Moscow, Russia;7. Radiology Service, Hospital General de México “Dr Eduardo Liceaga”, 06720, Mexico City, Mexico;1. Center of Clinical Medical Research, The Affiliated Suqian First People''s Hospital of Xuzhou Medical University, Suqian, Jiangsu, China;1. Institute of Molecular Biology & Translational Medicine, The Affiliated People''s Hospital, Jiangsu University, Zhenjiang, Jiangsu, China |
| |
| Abstract: | Percutaneous balloon mitral valvuloplasty (PBMV) is primarily performed for rheumatic mitral stenosis (MS). Therefore, limited data exist on PBMV in countries with a low incidence of rheumatic disease. Using the Nationwide Readmission Database, we examined trends in in-hospital mortality and 30-day readmission among patients who received PBMV for rheumatic and non-rheumatic MS. We also examined the change in 90-day hospitalization rate before vs after PBMV. Between 2016 and 2019, there were 1109 hospitalizations in which patients received PBMV for rheumatic (n = 955, 86.1%) vs non-rheumatic MS (n = 154, 13.9%). The all-cause in-hospital mortality for rheumatic and non-rheumatic MS did not change over time (0.9% → 2.0%, P = 0.94, and 5.9% → 9.5%, P = 0.09 respectively). Similarly, the 30-day readmission for patients with rheumatic and non-rheumatic MS did not change over time (12.4% → 9.9%, P = 0.26, and 4.4% → 10.5%, P = 0.30, respectively). The 90-day all-cause hospitalization rate remained the same before vs after PBMV for rheumatic and non-rheumatic MS (25.5% → 21.8%; P = 0.14, and 24.0% → 33.7%; P = 0.19, respectively). Although no statistically significant change was noted over time for trends in in-hospital mortality, 30-day readmission, or even in the change in 90-day all-cause hospitalizations before and after PBMV for both types of MS, among those with non-rheumatic MS, there was a signal of an increase in the in-hospital mortality, and 30-day readmission, even more, there was 29% relative increase in 90-day hospitalizations after PBMV. Future studies are needed to examine the role of PBMV in patients with non-rheumatic MS. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
